Table 8. Multivariate analyses of clinicopathologic parameters on recurrence-free and overall survival in all patients (n=1218).
|
Recurrence-free survivala
|
Overall survivala
|
||||
|---|---|---|---|---|---|
| Variables | No. of patients | OR (95% CI) | P-value | OR (95% CI) | P-value |
| Age, years | |||||
| As continuous variable | 1218 (100%) | 1.04 (1.03–1.06) | <0.001 | 1.05 (1.03–1.06) | <0.001 |
| Histology | |||||
| SCCa | 996 (81.8%) | Reference | Reference | ||
| AdCa | 222 (18.2%) | 2.07 (1.37–3.12) | 0.001 | 2.56 (1.65–3.96) | <0.001 |
| Tumour size, cm | |||||
| ⩽2 | 571 (46.9%) | Reference | Reference | ||
| 2–4 | 510 (41.9%) | 2.11 (1.34–3.31) | 0.001 | 2.06 (1.27–3.37) | 0.004 |
| 4–6 | 114 (9.4%) | 3.55 (2.00–6.31) | <0.001 | 3.02 (1.59–5.72) | 0.001 |
| >6 | 23 (1.9%) | 5.48 (2.17–13.81) | <0.001 | 4.60 (1.64–12.93) | 0.004 |
| Parametrial involvement | |||||
| No | 1106 (90.8%) | Reference | Reference | ||
| Yes | 112 (9.2%) | 2.04 (1.27–3.29) | 0.003 | 2.15 (1.25–3.70) | 0.005 |
| Lymph node metastasis | |||||
| No | 1111 (85.5%) | Reference | Reference | ||
| Yes | 188 (14.5%) | 2.07 (1.35–3.18) | 0.001 | 2.27 (1.41–3.64) | 0.001 |
Abbreviations: AdCa, adenocarcinoma; CI, confidence interval; OR, odds ratio; LVSI=lymphovascular space invasion; SCCa, squamous cell carcinoma;
a
The analysis included age, FIGO stage, histology, tumour size, depth of stromal invasion, parametrial involvement, resection margin, LVSI, lymph node metastasis and adjuvant treatment.